Coagulation and fibrosis in chronic liver disease

Gut

Volumn 57, Issue 12, 2008, Pages 1722-1727

  Calvaruso, V ^a   Maimone, S ^a   Gatt, A ^a   Tuddenham, E ^a   Thursz, M ^b   Pinzani, M ^c   Burroughs, A K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Gastroenterology and Hepatology Research   (United Kingdom)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; CONNECTIVE TISSUE GROWTH FACTOR; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; FIBRIN; FIBRINOGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PENTOXIFYLLINE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; SSR 182289; THROMBIN; THROMBIN INHIBITOR; THROMBIN RECEPTOR; TINZAPARIN; UNCLASSIFIED DRUG;

BLOOD CLOTTING; CELL ACTIVATION; CELL PROLIFERATION; CHRONIC LIVER DISEASE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM CELL; FIBROGENESIS; GENE MUTATION; HEMOPHILIA; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; LIVER ISCHEMIA; LIVER NECROSIS; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CHRONIC DISEASE; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; KUPFFER CELLS; LIVER CIRRHOSIS; LIVER DISEASES; MALE; RATS; RECEPTORS, PROTEINASE-ACTIVATED; RECEPTORS, THROMBIN; THROMBIN; WOUND HEALING;

EID: 56549119602     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.150748     Document Type: Review

References (48)

1. Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Digest Liver Dis 2004;36:231-42.
2. Friedman SL. Liver fibrosi - from bench to bedside. J Hepatol 2003;38:S38-53.
3. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci 2007;112:265-80.
4. Coughlin SR. Thrombin signalling and protease activated receptors. Nature 2000;407:258-64.
5. Iredale JP. Models of livers fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007;117:539-48.
6. Marra F, Grandaliano G, Valente Aj. et al. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology 1995;22:780-7.
7. Marra F, De Franco R, Grappone C, et al. Expression of the thrombin receptor in human liver: upregulation during acute and chronic injury. Hepatology 1998;27:426-71.
8. Fiorucci S, Antonelli E, Distrutti E, et al. PAR1 antagonisms protects against experimental liver fibrosis, role of proteinase receptors in stellate cell activation. Hepatology 2004;39:365-75
9. Chambers RC, Dabbagh K. McAnulty RJ, et al. Thrombin simulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem J 1998;333:121-7.
10. Cunningham MA, Rondeau E, Chen X, et al. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 2000;191:455-62.
11. Cirino G, Cicala C, Bucci M, et al. Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med 1996;183:821-7.
12. Trejo J, Connolly A, Coughlin SR. The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. J Biol Chem 1996;271:21536-41.
13. Dabbagh K, Laurent GJ, McAnulty RJ, et al. Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism. Thromb Haemost 1998;79:405-9.
14. Camerer E, Huang W, Coughlin SR. Tissue F and factor X dependent activation of PAR2. Proc Natl Acad Sci U S A 2000;97:5255-60.
15. Riewald M, Ruf W. Mechanistic coupling of protease signalling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A 1999;98:7742-7.
16. Farrell DJ, Hines JE, Walls AF, et al. Inthrahepatic mast cells in chronic liver disease. Hepatology 1995;22:1175-81.
17. Schwartz LB, Irani AM, Roller K, et al. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 1987;138:2611-5.
18. Kyrialou D, Koroumalis E, Konsolas J, et al. Systemic mastocytosis: a rare cause of noncirrhotic portal hypertension simulating autoimmune cholongitas - report of four cases. Am J Gastroenterol 1998;93:106-8.
19. Fonga-Djimi HS, Gottrand F, Bonnevalle M, et al. A fatal case of portal hypertension complicating systemic mastocytosis in an adolescent. Eur J Pediatr 1995;154:819-21.
20. Gaça MDA, Zhou X, Benyon RC. Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J Hepatol 2002;36:362-9.
21. Chambers RC, Leoni P, Blanc-Brude OP, et al. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor 1. J Biol Chem 2000;275:35584-91.
22. Bezerra J, Bugge TH, Melin-Aldan H, et al. Plasminogen deficiency leads to impaired remodelling after a toxic injury to the liver. Proc Natl Acad Sci U S A 1999;96:15143-8.
23. Lee Ng V, Sabla GE, Melin-Aldan H, et al. Plaminogen deficiency results in poor clearance of non-fibrin matrix and persitent activation of hepatic stellate cells after an acute injury. J Hepatol 2001;35:781-9.
24. Papatheodoridis GV, Papakonstantinou E, Andrioti E, et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003;52:404-9.
25. Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatits C virus infection. Gut 2003;52:1206-10.
26. Poujol-Robert A, Rosmorduc O, Serfaty L, et al. Genetic and acquired thrombotic factors in chronic hepatitis C. Am J Gastroenterol 2004;99:527-31.
27. Adinolfi LE, Ingrosso D, Cesaro G, et al. Hyperhomocysteinemia and the MTHFR C677T polymorophism promote steatosis and fibrosis in chronic hepatitis C. Hepatology 2005;41:995-1003.
28. Goulding C, O'Brien C, Egan H, et al. The impact of inherited prothrombic risk factors on individuals chronically infected with hepatitis C virus from a single source. J Viral Hepatitis 2006;14:255-9.
29. Hillebrandt S, Wasmuth HE, Weiskirchen R, et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 2005;37:8.
30. Assy N, Pettigrew N, Lee SS, et al. Are chronic hepatitis C viral infections more benign in patients with hemophilia? Am J Gastroenterol 2007;102:1672-6.
31. Wanless IR, Beljiorno J, Huet PM. Hepatic sinusoidal fibrosis induced by cholesterol and stilbestrol in the rabbit: 1. Morphology and inhibition of fibrogenesis by dipyridamole. Hepatology 1996;24:855-64.
32. Breddin HK. Current perspectives in the antiplatelet therapy of thrombotic disorders. Semin Thromb Hemost 1989;15:144-9.
33. Romanelli RG, Caligiuri A, Carloni V, et al. Effects of pentoxifylline on degradation of procollagen type I produced by human hepatic stellate cells in response to transforming growth factor-β1. Br J Pharmacol 1997;122:1047-54.
34. Pinzani M, Marra F, Caligiuri A, et al. Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells. Br J Pharmacol 1996;119:1117-24.
35. Gillibert Duplantier J, Dubuisson L, Senant N, et al. A role for thrombin in liver fibrosis. Gut 2004;53:1682-7.
36. Li G, Xie Q, Shi Y, et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006;8:889-900.
37. Assy N, Hussain O, Khalil A, et al. The beneficial effects and enoxaparin on fibrosis progression and regenerative activity in the rat model of cirrhosis. Dig Dis Sci 2007;52:1187-93.
38. Gordring MB, Krane SM. Modulation by recombinant interleukin-1 of synthesis of type 1 and 111 collagen and associated procollagen RNA levels in cultured human cells. J Biol Chem 1987;262:16724-9.
39. Abdel-Salam OME, Baiuomy AR, Ameen A, et al. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res 2005;51:59-67.
40. Abe W, Ikejima K, Lang T. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol 2007;46:286-94.
41. Shi J, Hao JH, Ren WH. Effects of heparin on liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2003;9:1611-4.
42. Wanless IR, Wong F, Blendis LM, et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in the development of parenchymal extinction and portal hypertension. Hepatology 1995;21:1238-47.
43. Kayo S, Ikura Y, Suekane T, et al. Close association between activated platelets and neutrophils in the active phase of ulcerative colitis in humans. Inflamm Bowel Dis 2006;12:727-35.
44. Ikuta T, Naruko T, Ikura Y, et al. Immunolocalization of platelet glycoprotein IIb/IIIa and P-selectine and neutrophil-platelet interaction in human coronary unstable plaques. Int J Mol Med 2005;15:573-7.
45. O'Sullivan BP, Linden MD, Frelinger AL 3rd, et al. Platelet activation in cystic fibrosis. Blood 2005;105:4635-41.
46. Novo E, Cannitto S, Zamara E, et al. Proangiogenic cytochines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007;170:1942-53.
47. Samonakis DN, Cholongitas E, Thalheimer U, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transplant 2007;13:1305- 11.
48. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006;43:492-9.